Please login to the form below

Not currently logged in
Email:
Password:

Zocor

This page shows the latest Zocor news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects cardiovascular outcomes claim for Vytorin

FDA panel rejects cardiovascular outcomes claim for Vytorin

expire. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent brand Zocor) alone

Latest news

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics